Molecular Partners AG
NASDAQ:MOLN
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Realty Income Corp
NYSE:O
|
Real Estate
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
3.32
11.01
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
Abbvie Inc
NYSE:ABBV
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Realty Income Corp
NYSE:O
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one MOLN stock under the Base Case scenario is 3.37 USD. Compared to the current market price of 4.67 USD, Molecular Partners AG is Overvalued by 28%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Molecular Partners AG
Run backtest to discover the historical profit from buying and selling MOLN based on its intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Price Target |
Loading
|
Revenue Forecast |
|
Operating Income Forecast |
|
Earnings Forecast |
|
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Molecular Partners AG
Balance Sheet Decomposition
Molecular Partners AG
Current Assets | 165.6m |
Cash & Short-Term Investments | 159.1m |
Receivables | 3.4m |
Other Current Assets | 3.1m |
Non-Current Assets | 5m |
PP&E | 4.9m |
Intangibles | 122k |
Current Liabilities | 11.4m |
Accounts Payable | 2.9m |
Accrued Liabilities | 6.7m |
Other Current Liabilities | 1.8m |
Non-Current Liabilities | 3.7m |
Long-Term Debt | 1.8m |
Other Non-Current Liabilities | 1.9m |
Earnings Waterfall
Molecular Partners AG
Revenue
|
10.4m
CHF
|
Operating Expenses
|
-85.9m
CHF
|
Operating Income
|
-75.5m
CHF
|
Other Expenses
|
6.4m
CHF
|
Net Income
|
-69.1m
CHF
|
Free Cash Flow Analysis
Molecular Partners AG
CHF | |
Free Cash Flow | CHF |
MOLN Profitability Score
Profitability Due Diligence
Molecular Partners AG's profitability score is 30/100. The higher the profitability score, the more profitable the company is.
Score
Molecular Partners AG's profitability score is 30/100. The higher the profitability score, the more profitable the company is.
MOLN Solvency Score
Solvency Due Diligence
Molecular Partners AG's solvency score is 75/100. The higher the solvency score, the more solvent the company is.
Score
Molecular Partners AG's solvency score is 75/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MOLN Price Targets Summary
Molecular Partners AG
According to Wall Street analysts, the average 1-year price target for MOLN is 8.76 USD with a low forecast of 3.6 USD and a high forecast of 18.69 USD.
Shareholder Yield
Current shareholder yield for MOLN is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
MOLN Price
Molecular Partners AG
Average Annual Return | -12.34% |
Standard Deviation of Annual Returns | 38.39% |
Max Drawdown | -90% |
Market Capitalization | 155m USD |
Shares Outstanding | 33 182 600 |
Percentage of Shares Shorted | 0.11% |
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. The company is headquartered in Schlieren, Zuerich and currently employs 163 full-time employees. The company went IPO on 2014-10-22. The firm has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
Contact
IPO
Employees
Officers
The intrinsic value of one MOLN stock under the Base Case scenario is 3.37 USD.
Compared to the current market price of 4.67 USD, Molecular Partners AG is Overvalued by 28%.